B2BROKER
B2BinPay, the leading crypto payment processor, has once again raised the bar with its latest v18 solution update. Building upon the success of their previous v17 release, the company has introduced significant advancements for their clients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231116251906/en/
B2BinPay v18 update introduces Account Merge - Unifying Merchant and Enterprise Models and streamlining onboarding and business management processes. The update also comes with a fully renewed front-end and enhanced regulatory compliance. (Graphic: Business Wire)
The new release boasts a unified account system, merging the Merchant and Enterprise models and making transaction management easier than ever before. Coupled with a revamped front end and reinforced regulatory compliance, B2BinPay continues to prioritise UX and security in this latest version.
Let’s explore these cutting-edge updates further.
Account Unification
This update brings about a new philosophy in how B2BinPay delivers its services by unifying the two business models (Merchant and Enterprise) into one user-friendly interface.
What exactly does this mean for B2BinPay's clients? It means a more streamlined and integrated experience, as the platform combines both the Merchant and Enterprise account functionality into one user-friendly interface, which means clients can now manage all their transactions within a single, unified system.
But the benefits don't stop there. The account unification also simplifies the registration process, making it easier for businesses to join the platform and use its services immediately. With equal conditions and a single, unified onboarding fee for all types of users, clients have the freedom to choose and transition between services as their business needs evolve without the worry of extra costs or complex administrative processes. With this new approach, businesses can focus on what truly matters – their growth.
Revamped Front-End and Richer Functionality
The v18 release features a redesigned front end that not only aligns with the sleek aesthetic of the B2Broker brand but also offers improved speed and security for users. The core features that have made B2BinPay a favourite among its users have been maintained, ensuring a smooth transition to the updated platform. Here are the sections that have been completely redesigned:
- Wallets & Transfers
With a sleeker layout and optimised processes, users can quickly navigate through wallets & transfers sections without extra clicks and lengthy loadings. The update streamlines all financial operations, including payouts, bank withdrawals, and exchanges, providing a more seamless and time-saving experience for B2BinPay users.
- Account Menu
The renewed Account Menu features an intuitive, more user-friendly and secure design. Users can now easily manage their preferences, control API permissions, and customise their profile from one central location. Additionally, the 2FA feature adds an extra layer of security to protect user accounts from unauthorised access.
The Payment Page has also been revamped to reflect the updated design philosophy of B2Broker. This ensures that all financial transactions are carried out in a protected environment.
- Helpdesk
The updated Helpdesk provides a more streamlined and user-friendly experience for users. With a more defined schedule for multilingual support and new sticker notifications for incoming messages, users can now keep track of their inquiries more efficiently and receive timely responses from the B2BinPay team.
- Rates Interface
The Rates interface has undergone several upgrades. One of the major changes is that Rates now have richer filtering and favourites options. Additionally, the section can now be accessed directly from the top-level menu instead of being hidden in Wallets.
- Flexible Invoices
B2BinPay has removed the previous 7-day limit on merchant invoice expiration, allowing for customisation of timelines to fit each business's specific requirements better.
Complying with FATF Travel Rule
The v18 update brings enhanced Travel Rule compliance to the forefront. By partnering with Notabene, a leading provider of Travel Rule solutions, B2BinPay ensures strict adherence to the Financial Action Task Force (FATF) Travel Rules regulations.
The FATF Travel Rule requires VASPs, including B2BinPay, to collect and share personal information in cryptocurrency transactions to prevent money laundering and other unethical practices. New integration equipped B2BinPay with a robust system for detecting suspicious activities and eliminating fraud, providing clients with added peace of mind.
Final Remarks
In light of the growing popularity and acceptance of cryptocurrency, B2BinPay has established itself as a reliable and trustworthy solution in providing efficient crypto payment architecture for businesses. The launch of their v18 update showcases their commitment to constantly improving and expanding their services, staying ahead of market trends and regulatory standards.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116251906/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom